MA39711A - Conjugués d'une fraction d'il-15 et d'un polymère - Google Patents

Conjugués d'une fraction d'il-15 et d'un polymère

Info

Publication number
MA39711A
MA39711A MA039711A MA39711A MA39711A MA 39711 A MA39711 A MA 39711A MA 039711 A MA039711 A MA 039711A MA 39711 A MA39711 A MA 39711A MA 39711 A MA39711 A MA 39711A
Authority
MA
Morocco
Prior art keywords
conjugates
moiety
polymer
nonpeptidic
methods
Prior art date
Application number
MA039711A
Other languages
English (en)
Inventor
Thomas Chang
Deborah H Charych
Peter Benedict Kirk
Xiaofeng Liu
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MA39711A publication Critical patent/MA39711A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des conjugués d'une fraction d'il-11 et d'un ou de plusieurs polymères non peptidiques, solubles dans l'eau. Typiquement, le polymère non peptidique, soluble dans l'eau est un poly(éthylène glycol) ou un dérivé de celui-ci. L'invention porte également, entre autres, sur des compositions comprenant des conjugués, des procédés de fabrication de conjugués et des procédés d'administration de compositions à un individu.
MA039711A 2014-04-03 2015-03-31 Conjugués d'une fraction d'il-15 et d'un polymère MA39711A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461974914P 2014-04-03 2014-04-03

Publications (1)

Publication Number Publication Date
MA39711A true MA39711A (fr) 2015-10-08

Family

ID=54241432

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039711A MA39711A (fr) 2014-04-03 2015-03-31 Conjugués d'une fraction d'il-15 et d'un polymère

Country Status (12)

Country Link
US (1) US20170035898A1 (fr)
EP (2) EP3139947B8 (fr)
JP (2) JP6728055B2 (fr)
KR (1) KR102432169B1 (fr)
CN (1) CN106456716A (fr)
AU (3) AU2015240806B2 (fr)
CA (1) CA2942571C (fr)
ES (1) ES2876433T3 (fr)
IL (1) IL248169A0 (fr)
MA (1) MA39711A (fr)
MX (2) MX388865B (fr)
WO (1) WO2015153753A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
JP2016528879A (ja) 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
HK1226308A1 (zh) 2013-08-30 2017-09-29 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
KR20170068553A (ko) 2014-10-14 2017-06-19 아르모 바이오사이언시스 인코포레이티드 인터류킨-15 조성물 및 이의 용도
JP6675394B2 (ja) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
MA47290A (fr) 2015-10-08 2019-11-27 Nektar Therapeutics Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
MX2018007304A (es) * 2015-12-21 2019-03-14 Armo Biosciences Inc Composiciones de interleucina-15 y sus usos.
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN111093688B (zh) * 2017-05-15 2025-09-16 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
WO2019165453A1 (fr) 2018-02-26 2019-08-29 Synthorx, Inc. Conjugués d'il-15 et leurs utilisations
AU2019376164B2 (en) * 2018-11-09 2025-10-16 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
SG11202111175YA (en) * 2019-04-26 2021-11-29 Prolynx Llc Slow-release cytokine conjugates
US11248025B2 (en) 2019-06-03 2022-02-15 Medikine, Inc. IL-2alpha receptor subunit binding compounds
PH12022500004A1 (en) * 2019-08-23 2023-04-03 Synthorx Inc Il-15 conjugates and uses thereof
AU2022249281B2 (en) * 2021-03-29 2025-08-14 Aj Sciences (Yixing) Co., Ltd Protein-macromolecule conjugates and methods of use thereof
IL309522B2 (en) 2021-06-23 2025-12-01 Cytune Pharma Interleukin 15 variants
WO2023288226A2 (fr) * 2021-07-12 2023-01-19 Nektar Therapeutics Formes polymères modifiées de l'interféron-gamma et procédés d'utilisation
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2025101551A1 (fr) * 2023-11-06 2025-05-15 Regents Of The University Of Minnesota Peptides de liaison à l'antigène membranaire spécifique de la prostate (psma) et procédé d'utilisation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ATE293168T1 (de) * 1993-11-12 2005-04-15 Gilead Sciences Inc Thrombin mutanten
PT772624E (pt) 1994-04-06 2001-03-30 Immunex Corp Interleucina-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6362254B2 (en) 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
JP4490290B2 (ja) * 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
JP2007506789A (ja) * 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
WO2006017853A2 (fr) * 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Composition contenant une interleukine-15 mutante et suppression de la reponse immunitaire
JP2008515896A (ja) 2004-10-05 2008-05-15 オクスナー クリニック ファウンデーション Ｉｌ−１５によるｂ細胞増殖の増強
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
PT2279758E (pt) 2005-06-16 2015-05-27 Nektar Therapeutics Conjugados possuindo uma ligação degradável e reagentes poliméricos úteis na preparação de tais conjugados
CN101686687A (zh) 2007-02-28 2010-03-31 塞瑞纳治疗公司 活化的聚噁唑啉及包含该聚噁唑啉的组合物
WO2010048184A2 (fr) * 2008-10-21 2010-04-29 Baxter International Inc. Procédés pour déterminer des substances actives dans des conjugués promédicament-peg-protéine avec des agents peg libérables (dépégylation in vitro)
AU2011282571C1 (en) * 2010-07-30 2018-04-05 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
KR102591732B1 (ko) * 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (fr) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugués d'une fraction il-11 et d'un polymère

Also Published As

Publication number Publication date
EP3919071A1 (fr) 2021-12-08
EP3139947B1 (fr) 2021-05-26
AU2015240806A1 (en) 2016-10-13
EP3139947A4 (fr) 2018-01-17
AU2015240806B2 (en) 2019-09-19
CN106456716A (zh) 2017-02-22
AU2021258008A1 (en) 2021-11-25
IL248169A0 (en) 2016-11-30
US20170035898A1 (en) 2017-02-09
EP3139947B8 (fr) 2021-06-30
JP2017511322A (ja) 2017-04-20
AU2019283778A1 (en) 2020-01-16
EP3139947A2 (fr) 2017-03-15
JP6728055B2 (ja) 2020-07-22
CA2942571A1 (fr) 2015-10-08
CA2942571C (fr) 2023-09-19
MX388865B (es) 2025-03-20
ES2876433T3 (es) 2021-11-12
JP2020114875A (ja) 2020-07-30
MX2021015492A (es) 2022-02-22
WO2015153753A3 (fr) 2015-11-26
KR102432169B1 (ko) 2022-08-11
MX2016012908A (es) 2017-01-11
WO2015153753A2 (fr) 2015-10-08
KR20170005793A (ko) 2017-01-16

Similar Documents

Publication Publication Date Title
MX2021015492A (es) Conjugados de un resto de interleucina-15 (il-15) y un polimero.
MX2017011562A (es) Conjugados de un resto de il-7 y un polimero.
MX382791B (es) Conjugados novedosos de glicano y uso de los mismos
SG10201909805XA (en) Surface modified polymer compositions
MX2016009943A (es) Composiciones de nanotribologia y metodos relacionados que incluyen nanolaminas moleculares.
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2013005363A (es) Conjugados de un resto de interleucina-2 y un polimero.
EP3037475A4 (fr) Ester actif de phénoxycyclotriphosphazène, composition de résine sans halogènes et son utilisation
EP4252681A3 (fr) Objets implantables, dispositifs de guidage, et procédés d'utilisation
MX2013007230A (es) Sistemas de polimero.
WO2015035342A3 (fr) Conjugués polymère zwittérionique-facteur viii
WO2016022943A3 (fr) Nouveaux monomères dérivés de biomasse
WO2013020079A3 (fr) Conjugués d'une fraction il-11 et d'un polymère
EP3510117A4 (fr) Compositions de lignine glyoxalée
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
MX385886B (es) Macromoleculas estrellas compatibles con tensoactivos.
MY195399A (en) Mixed Decyl Mercaptans Compositions and Methods Of Making Same
EP3478663A4 (fr) Polymère fonctionnalisé par un lactame, compositions et applications de celui-ci
MX2018005085A (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas.
IL259891A (en) Organic solvent free compositions comprising protein-polymer conjugates and uses thereof
MY191782A (en) A process to prepare a polyester polymer and a polyester polymer obtainable thereby
TW201614007A (en) Composition for forming silica layer, silica layer, and electronic device
EP3137517A4 (fr) Copolymère à faible teneur en oligomère cyclique
MX2020002908A (es) Composicion acuosa de polimeros.